Laboratory Corp. of America Holdings struck a deal to buy Chiltern International Ltd. for $1.2 billion in a move to grow its stake in the drug development and contract-research industry. LabCorp expects the acquisition to add to adjusted earnings within one year and to earn back its cost of capital in three years. The Burlington, N.C.-based life-science and technologies company said Chiltern will become part of its Covance...

Source: Wall Street Journal July 31, 2017 11:37 UTC